Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board
(NL version) | go backOncology focused biopharmaceutical product development company Kiadis Pharma announces today that Mark Skaletsky was elected to its Supervisory Board as an independent board member.
Manja Bouman, Chief Executive Officer, says: “I am very pleased that Mark Skaletsky joins the supervisory board of Kiadis Pharma. He has a long and impressive career as a senior executive with several successful biopharmaceutical companies. His input will be invaluable as we prepare for the next steps in the development of our products.
“I am excited to have the opportunity to join Kiadis Pharma’s Supervisory Board. I believe I am joining the company at a very exciting time with its lead product ATIR™ ready to move into a pivotal study,” says Mark Skaletsky. “Kiadis Pharma has unique products in development that have the potential to fulfill a high unmet medical need, specifically for patients in need of a bone marrow transplantation, and I look forward to assisting the company as it advances.”
Mr. Skaletsky has a long outstanding track record within the biotech industry. He served as president and CEO of GelTex Pharmaceuticals, Inc. (acquired by Genzyme for more than $1 billion in December 2000), chairman and CEO of Enzytech, Inc., and president and Chief Operating Officer of Biogen, Inc. He is also a former chairman of the board of directors of the Biotechnology Industry Organization (BIO). Mr. Skaletsky is chairman, CEO and president of Fenway Pharmaceuticals, Inc.
